Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken-Hong Lim

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Blood|August 29, 2009
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignanciesAnimesh Pardanani, Ken-Hong Lim, Terra L Lasho, et al.
Medical Oncology (Northwood, London, England)|October 6, 2007
Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancerKen-Hong Lim, Ming-Jer Huang, Hung-Chang Liu, et al.
BMC Cancer|October 18, 2019
STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancersYi-Fang Chang, Ken-Hong Lim, Ya-Wen Chiang, et al.
Anti-Cancer Drugs|June 19, 2004
Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization scheduleKen-Hong Lim, Ming-Jer Huang, Huan-Chau Lin, et al.
Asia-Pacific Journal of Clinical Oncology|August 18, 2012
Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtypeYi-Hao Chiang, Yi-Fang Chang, Ruey-Kuen Hsieh, et al.
Frontiers in Immunology|February 2, 2019
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid LeukemiaMing-Chin Chang, Hung-I Cheng, Kate Hsu, et al.
Blood|April 14, 2009
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factorsKen-Hong Lim, Ayalew Tefferi, Terra L Lasho, et al.
Cancer Reports (Hoboken, N.J.)|November 29, 2025
Daratumumab-Based Combinational Therapy as Second-Line Treatment of Relapsed-Refractory Multiple Myeloma: A Single-Center ExperienceOscar C Y Yang, Yi-Hao Chiang, Caleb Gonshen Chen, et al.
Cell Death & Disease|October 2, 2020
BAFF-driven NLRP3 inflammasome activation in B cellsKen-Hong Lim, Lih-Chyang Chen, Kate Hsu, et al.
Medical Oncology (Northwood, London, England)|May 20, 2008
Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumorsKen-Hong Lim, Ming-Jer Huang, Li-Tzong Chen, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Blood|August 29, 2009
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignanciesAnimesh Pardanani, Ken-Hong Lim, Terra L Lasho, et al.
Medical Oncology (Northwood, London, England)|October 6, 2007
Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancerKen-Hong Lim, Ming-Jer Huang, Hung-Chang Liu, et al.
BMC Cancer|October 18, 2019
STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancersYi-Fang Chang, Ken-Hong Lim, Ya-Wen Chiang, et al.
Anti-Cancer Drugs|June 19, 2004
Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization scheduleKen-Hong Lim, Ming-Jer Huang, Huan-Chau Lin, et al.
Asia-Pacific Journal of Clinical Oncology|August 18, 2012
Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtypeYi-Hao Chiang, Yi-Fang Chang, Ruey-Kuen Hsieh, et al.
Frontiers in Immunology|February 2, 2019
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid LeukemiaMing-Chin Chang, Hung-I Cheng, Kate Hsu, et al.
Blood|April 14, 2009
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factorsKen-Hong Lim, Ayalew Tefferi, Terra L Lasho, et al.
Cancer Reports (Hoboken, N.J.)|November 29, 2025
Daratumumab-Based Combinational Therapy as Second-Line Treatment of Relapsed-Refractory Multiple Myeloma: A Single-Center ExperienceOscar C Y Yang, Yi-Hao Chiang, Caleb Gonshen Chen, et al.
Cell Death & Disease|October 2, 2020
BAFF-driven NLRP3 inflammasome activation in B cellsKen-Hong Lim, Lih-Chyang Chen, Kate Hsu, et al.
Medical Oncology (Northwood, London, England)|May 20, 2008
Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumorsKen-Hong Lim, Ming-Jer Huang, Li-Tzong Chen, et al.
Pageof 4